JSPR earnings analysis
What we found in JSPR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures needed to assess quarterly revenue, margins, EPS, working capital, or free cash flow. Financial-condition disclosures remain concerning: as of June 30, 2026, cash was $7.3 million, six-month operating cash flow was negative $21.5 million, and management stated that substantial doubt exists about going-concern status, although the company subsequently raised approximately $131.6 million. The July Kira merger adds significant integration, dilution, preferred-stock redemption, and Nasdaq compliance risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Post-quarter financing materially increased liquidity
- Jasper raised approximately $131.6 million of net proceeds in the 2026 Financing completed on July 20, 2026, compared with cash and cash equivalents of $7.3 million at June 30, 2026.
- Year-to-date losses and cash burn improved
- Six-month net loss improved to $3.9 million from $48.0 million in the comparable 2025 period, while negative operating cash flow improved to $21.5 million from $38.3 million.
- New license creates potential milestone upside
- The Mirador License Agreement provides potential milestone economics of up to $108.5 million in development and regulatory payments and up to $350.0 million in commercial, net-sales-based payments, plus tiered royalties.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern uncertainty remains
- Management concluded that substantial doubt exists about the company's ability to continue as a going concern beyond one year from the filing date. Jasper reported cash of $7.3 million at June 30, 2026, negative operating cash flow of $21.5 million for the six months ended June 30, 2026, and an accumulated deficit of $320.6 million.
- Preferred-stock approval creates cash risk
- If stockholders do not approve conversion and other Company Stockholder Matters within 12 months after the initial issuance of Convertible Preferred Stock, holders may elect cash redemption. Each preferred share is convertible into 61 common shares subject to approval, creating substantial potential cash-settlement exposure and dilution.
- Nasdaq minimum-bid deficiency
- Nasdaq notified Jasper on June 3, 2026 that its bid price had closed below $1.00 for 30 consecutive business days. The company has until November 30, 2026 to regain compliance, potentially requiring a reverse stock split.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. Management states it will continue to incur significant expenses and increasing operating losses for the foreseeable future and will need additional financing for the foreseeable future.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Jasper Therapeutics reported significant operational improvements in its latest 10-Q, with revenues remaining at zero but a notable reduction in net losses and cash burn. The company plans to continue focusing on its…
- 10-K · April 30, 2026
- Jasper Therapeutics remains firmly in the clinical stage, aiming to treat mast-cell driven diseases with varying success across trials. The company reported a substantial net loss of $75.8 million in 2025, reflecting…
- 10-K · March 30, 2026
- Jasper is a clinical‑stage biotech focused exclusively on mast‑cell driven diseases, advancing its lead candidate briquilimab through multiple Phase 1b/2a programs (CSU BEACON, CIndU SPOTLIGHT, asthma ETESIAN) with…
- 10-Q · November 7, 2024
- Jasper reported a Q3 net loss of $18,637 thousand and GAAP EPS of $(1.24), compared with a net loss of $17,544 thousand and EPS of $(1.60) in Q3 2023. Cash and cash equivalents increased to $92,502 thousand (from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing JSPR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever